PURPOSE: Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines and xenografts, alone and with endocrine therapy. This phase Ib study evaluated buparlisib plus letrozole's safety, tolerability, and preliminary activity in patients with metastatic ER-positive breast cancer refractory to endocrine therapy. PATIENTS AND METHODS: Patients received letrozole and buparlisib in two different administration schedules. Outcomes were assessed by standard solid-tumor phase I methods. [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography ([(18)F]FDG-PET/CT) scans were done at baseline and 2 weeks after treatment initiation. Tumor blocks were collected for phosphoinositide-3-kinase pathway mutation analysis. RESULTS: Fifty-one patients were allocated sequentially to continuous or intermittent (five on/two off days) buparlisib administration on an every-4-week schedule. Buparlisib's maximum-tolerated dose (MTD) was 100 mg/d. Common drug-related adverse events included ≤ grade 2 hyperglycemia, nausea, fatigue, transaminitis, and mood disorders. The clinical benefit rate (lack of progression ≥ 6 months) among all patients treated at the MTD was 31%, including two objective responses in the continuous dose arm. Of seven patients remaining on treatment ≥ 12 months, three had tumors with PIK3CA hot-spot mutation. Patients exhibiting metabolic disease progression by [(18)F]FDG-PET/CT scan at 2 weeks progressed rapidly on therapy. CONCLUSION: The letrozole and buparlisib combination was safe, with reversible toxicities regardless of schedule administration. Clinical activity was observed independent of PIK3CA mutation status. No metabolic response by [(18)F]FDG-PET/CT scan at 2 weeks was associated with rapid disease progression. Phase III trials of buparlisib and endocrine therapy in patients with ER-positive breast cancer are ongoing.
PURPOSE:Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines and xenografts, alone and with endocrine therapy. This phase Ib study evaluated buparlisib plus letrozole's safety, tolerability, and preliminary activity in patients with metastatic ER-positive breast cancer refractory to endocrine therapy. PATIENTS AND METHODS: Patients received letrozole and buparlisib in two different administration schedules. Outcomes were assessed by standard solid-tumor phase I methods. [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography ([(18)F]FDG-PET/CT) scans were done at baseline and 2 weeks after treatment initiation. Tumor blocks were collected for phosphoinositide-3-kinase pathway mutation analysis. RESULTS: Fifty-one patients were allocated sequentially to continuous or intermittent (five on/two off days) buparlisib administration on an every-4-week schedule. Buparlisib's maximum-tolerated dose (MTD) was 100 mg/d. Common drug-related adverse events included ≤ grade 2 hyperglycemia, nausea, fatigue, transaminitis, and mood disorders. The clinical benefit rate (lack of progression ≥ 6 months) among all patients treated at the MTD was 31%, including two objective responses in the continuous dose arm. Of seven patients remaining on treatment ≥ 12 months, three had tumors with PIK3CA hot-spot mutation. Patients exhibiting metabolic disease progression by [(18)F]FDG-PET/CT scan at 2 weeks progressed rapidly on therapy. CONCLUSION: The letrozole and buparlisib combination was safe, with reversible toxicities regardless of schedule administration. Clinical activity was observed independent of PIK3CA mutation status. No metabolic response by [(18)F]FDG-PET/CT scan at 2 weeks was associated with rapid disease progression. Phase III trials of buparlisib and endocrine therapy in patients with ER-positive breast cancer are ongoing.
Authors: Steven J Isakoff; Jeffrey A Engelman; Hanna Y Irie; Ji Luo; Saskia M Brachmann; Rachel V Pearline; Lewis C Cantley; Joan S Brugge Journal: Cancer Res Date: 2005-12-01 Impact factor: 12.701
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: Gizeh Pérez-Tenorio; Liza Alkhori; Birgit Olsson; Marie Ahnström Waltersson; Bo Nordenskjöld; Lars Erik Rutqvist; Lambert Skoog; Olle Stål Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Katherine Stemke-Hale; Ana Maria Gonzalez-Angulo; Ana Lluch; Richard M Neve; Wen-Lin Kuo; Michael Davies; Mark Carey; Zhi Hu; Yinghui Guan; Aysegul Sahin; W Fraser Symmans; Lajos Pusztai; Laura K Nolden; Hugo Horlings; Katrien Berns; Mien-Chie Hung; Marc J van de Vijver; Vicente Valero; Joe W Gray; René Bernards; Gordon B Mills; Bryan T Hennessy Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Teresa F Ackermann; Heide Hörtnagl; David P Wolfer; Giovanni Colacicco; Reinhard Sohr; Florian Lang; Rainer Hellweg; Undine E Lang Journal: Cell Physiol Biochem Date: 2008-12-09
Authors: Josep Tabernero; Federico Rojo; Emiliano Calvo; Howard Burris; Ian Judson; Katharine Hazell; Erika Martinelli; Santiago Ramon y Cajal; Suzanne Jones; Laura Vidal; Nicholas Shand; Teresa Macarulla; Francisco Javier Ramos; Sasa Dimitrijevic; Ulrike Zoellner; Pui Tang; Michael Stumm; Heidi A Lane; David Lebwohl; José Baselga Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: Pieter J A Eichhorn; Magüi Gili; Maurizio Scaltriti; Violeta Serra; Marta Guzman; Wouter Nijkamp; Roderick L Beijersbergen; Vanesa Valero; Joan Seoane; René Bernards; José Baselga Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: Ana Bosch; Zhiqiang Li; Anna Bergamaschi; Haley Ellis; Eneda Toska; Aleix Prat; Jessica J Tao; Daniel E Spratt; Nerissa T Viola-Villegas; Pau Castel; Gerard Minuesa; Natasha Morse; Jordi Rodón; Yasir Ibrahim; Javier Cortes; Jose Perez-Garcia; Patricia Galvan; Judit Grueso; Marta Guzman; John A Katzenellenbogen; Michael Kharas; Jason S Lewis; Maura Dickler; Violeta Serra; Neal Rosen; Sarat Chandarlapaty; Maurizio Scaltriti; José Baselga Journal: Sci Transl Med Date: 2015-04-15 Impact factor: 17.956
Authors: S Chia; S Gandhi; A A Joy; S Edwards; M Gorr; S Hopkins; J Kondejewski; J P Ayoub; N Califaretti; D Rayson; S F Dent Journal: Curr Oncol Date: 2015-02 Impact factor: 3.677
Authors: Jennifer R Bean; Sarah R Hosford; Lynn K Symonds; Philip Owens; Lloye M Dillon; Wei Yang; Kevin Shee; Gary N Schwartz; Jonathan D Marotti; Kristen E Muller; Kari M Rosenkranz; Richard J Barth; Vivian S Chen; Veena R Agarwal; Todd W Miller Journal: Breast Cancer Res Treat Date: 2014-12-10 Impact factor: 4.872
Authors: Wei Yang; Sarah R Hosford; Lloye M Dillon; Kevin Shee; Stephanie C Liu; Jennifer R Bean; Laurent Salphati; Jodie Pang; Xiaolin Zhang; Michelle A Nannini; Eugene Demidenko; Darcy Bates; Lionel D Lewis; Jonathan D Marotti; Alan R Eastman; Todd W Miller Journal: Clin Cancer Res Date: 2016-01-05 Impact factor: 12.531
Authors: Ingrid A Mayer; Vandana G Abramson; Luigi Formisano; Justin M Balko; Mónica V Estrada; Melinda E Sanders; Dejan Juric; David Solit; Michael F Berger; Helen H Won; Yisheng Li; Lewis C Cantley; Eric Winer; Carlos L Arteaga Journal: Clin Cancer Res Date: 2016-04-28 Impact factor: 12.531